智通财经网·2025-09-09 06:53Core Viewpoint - Morgan Stanley upgraded the investment rating of Fosun Pharma (02196) from "In Line with Market" to "Overweight," citing a reassessment of its R&D pipeline and the undervaluation of its innovative drug portfolio [1] Group 1: Investment Rating and Target Price - The investment rating for Fosun Pharma has been raised to "Overweight" due to the perceived undervaluation of its innovative drug portfolio [1] - The target price for H-shares has been increased from HKD 20 to HKD 33 [1] Group 2: Financial Projections - The company is expected to see a 20% growth in net profit by 2025 [1] - The compound annual growth rate (CAGR) for net profit from 2025 to 2027 is projected to be 20% [1] Group 3: Strategic Moves - Continuous divestment of non-core assets is anticipated to enhance the company's financial capabilities [1] - These strategic moves are expected to lead to a turnaround in business performance and overall profit improvement [1]